Business Wire

Mavenir’s RCS Mobile Business Messaging Cloud Completes Interconnection between Telefónica, Vodafone, and Deutsche Telekom Germany

23.6.2020 16:00:00 EEST | Business Wire | Press release

Share

Mavenir, the industry’s only end-to-end, cloud-native Network Software Provider and a leader in messaging and Rich Communication Services (RCS) today announced its Mobile Business Messaging Cloud in Europe completed peer-to-peer (P2P) RCS interconnection with the networks of Telefónica (BME:TEF), Vodafone (OTCMKTS: VODPF) and Deutsche Telekom Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200623005331/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

This represents one of the largest RCS carrier interconnections achieved to date, with an estimated addressable market of more than 158 million RCS-upgradeable mobile subscribersi in 13 countries. This includes 3 Telefónica markets, 13 Vodafone markets, and Deutsche Telekom Germany, as well as other carriers.

With three MNOs currently under deployment, covering up to 40 million RCS upgradeable users, Mavenir Mobile Business Messaging Cloud is one of the largest RCS cloud services in the market with interconnection.

These interconnections allow MNOs choosing Mavenir’s Mobile Business Messaging Cloud to eliminate the technical complexities and costs of interconnecting with other MNOs in their regions of operation and lets them focus on commercial terms.

“Interconnecting with these partners required a significant amount of expertise and effort by all parties. Our engineering and operations teams worked very closely with their peers at Vodafone, Telefónica and Deutsche Telekom. It was a team effort, with all parties at the table willing to participate and it shows in the results,” said Guillaume Le Mener, SVP Business Mobility, Mavenir. “This milestone paves the way for accelerated and simplified future MNO onboarding and participation.”

Mavenir’s Mobile Business Messaging Cloud is a Software-as-a-Service (SaaS) RCS Business Messaging (RBM) implementation—operated by Mavenir—that allows MNOs to easily deliver consumer and business RCS messaging services. The cloud solution includes the RCS and IMS Cores, as well as the session border controllers (SBC) and firewalls required for RCS P2P messaging, and the MaaP (Messaging as a Platform) layer to deliver application-to-person (A2P) and person-to-application (P2A) business messaging to users, including chatbot experiences and advanced business messaging services.

Mavenir’s fully compliant with Universal Profile 2.0 RCS solution, supports enhanced mobile messaging features such as open group chat, delivery, is-typing, read notifications, image and file transfer, and audio/video messages for P2P communications. It also supports rich cards and rich card carousels, buttons and suggested responses, among other features, to provide enhanced A2P and P2A business messaging interactions with brands. The solution also leverages Mavenir’s growing Business Messaging Ecosystem, which has close to 70 members, including aggregators, chatbot and business application developers, as well as CPaaS providers.

About Mavenir:

Mavenir is the industry's only end-to-end, cloud-native Network Software Provider focused on accelerating software network transformation and redefining network economics for Communications Service Providers (CSPs). Mavenir offers a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging innovations in IMS (VoLTE, VoWiFi, Advanced Messaging (RCS), Private Networks as well as vEPC, 5G Core and OpenRAN vRAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 140 countries, which serve over 50% of the world’s subscribers.

Mavenir embraces disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation, and revenue protection. www.mavenir.com

Mavenir and the M logo are trademarks owned by Mavenir Systems, Inc.
Copyright © 2020 Mavenir Systems, Inc. All Rights Reserved.

_________
i Mavenir estimation based on Smartphone numbers and Android penetration per country from GSMA data and other sources.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Maryvonne Tubb
Mavenir PR

NA-Loren Guertin
MatterNow

EMEA-Kevin Taylor
GlobalResultsPR

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye